Immune checkpoint inhibitors: a promising anticancer therapy
| Autor: | Daniel Hassan, Nagashekhara Molugulu, Prashant Kesharwani, Rahul Shukla, Hibah M. Aldawsari, Sima Singh |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
0301 basic medicine
Drug Oncology medicine.medical_specialty T-Lymphocytes media_common.quotation_subject Immune checkpoint inhibitors Disease Patient response 03 medical and health sciences Antineoplastic Agents Immunological 0302 clinical medicine Immune system Neoplasms Internal medicine Drug Discovery medicine Animals Humans Adverse effect Immune Checkpoint Inhibitors media_common Pharmacology business.industry Cancer Therapeutic resistance medicine.disease 030104 developmental biology 030220 oncology & carcinogenesis business Biomarkers hormones hormone substitutes and hormone antagonists |
| Zdroj: | Drug Discovery Today. 25:223-229 |
| ISSN: | 1359-6446 |
| DOI: | 10.1016/j.drudis.2019.11.003 |
| Popis: | Immune checkpoint inhibitors (ICIs) are revolutionizing the treatment of many cancers and have demonstrated their potential as 'cancer terminators'. However, ICI treatment also has constraints, such as its immune-related adverse events (irAEs) and therapeutic resistance. These drawbacks are gradually being overcome through better knowledge of the immune system, history of disease, duration of treatment, combinational drug regimes, adequate biomarkers, and effective patient response monitoring. In this review, we discuss the present ICI therapy landscape and its therapeutic outcomes for various diseases. We also highlight biomarkers related to the ICI response. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect